<i>De Novo</i> Vogt-Koyanagi-Harada Disease following Covid-19 Vaccine: A Case Report and Literature Overview

Courssou, J.-B. Brunet de; Tisseyre, Mylène; Hadjadj, Jérôme; Chouchana, Laurent; Broca, Florent; Terrier, B.; Duraffour, Pierre; Henriquez, Soledad

doi:10.1080/09273948.2022.2028291

Cited by 14 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some cases of VKH disease cases have a poor visual prognosis, the six post-COVID19 vaccination de novo VKH cases summarized in Table 1 , including the current case, showed a relatively good short-term visual prognosis after systemic corticosteroid therapy. 3 , 4 , 5 , 6 , 7 Furthermore, VKH cases after COVID-19 vaccination are more likely to be female (5 cases, 83%), develop after the first dose (5 cases, 83%), have visual symptom within one week after vaccination (4 cases, 67%), and have SRD-type VKH (5 cases, 83%). The preponderance of SRD-type VKH disease is similar to general VKH disease, 21 and since patients with optic disc swelling-type VKH disease have been reported to be more likely to develop chronic disease than patients with SRD-type VKH disease, 21 the risk of developing chronic disease might also be lower in post-COVID-19 vaccination cases of VKH.…”

Section: Discussionmentioning

confidence: 99%

“… 1 , 2 Vogt-Koyanagi-Harada (VKH) disease after vaccination is rare, and its prognosis remains unclear. 3 , 4 , 5 , 6 , 7 VKH disease is known as a type of bilateral uveitis associated with alopecia, metamorphopsia (a disorder in which the shape of objects appears distorted), vitiligo, poliosis, dysacousia, meningeal irritation abnormalities of the cerebrospinal fluid, 8 and ocular circulation impairment. 9 , 10 The current report describes the first reported Japanese case of VKH disease two weeks after administration of a second dose of a COVID-19 mRNA vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy

Yamaguchi

Kunikata

Hashimoto

et al. 2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy

Yamaguchi

Kunikata

Hashimoto

et al. 2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

“…A total of 65 studies were both qualitatively and quantitatively analyzed ( Table 1 ) [ 1 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events.

show abstract

“…[ 11 ] VKH following COVID-19 vaccinations has also been reported. [ 12 13 14 15 ] Papasavvas and Herbort presented a case of chronic VKH reactivation 6 weeks after administration of the second dose of BNT162b2; the authors proposed that the altered RNA metabolism with overactive Toll-like receptors induced the reactivation. [ 13 ] Our case 8, on the contrary, was a de novo acute VKH disease.…”

Section: Discussionmentioning

confidence: 99%

Ocular inflammatory manifestations following COVID-19 vaccinations in Taiwan: A case series

Hsu¹,

Wang²,

Chen³

et al. 2022

Taiwan J Ophthalmol

View full text Add to dashboard Cite

As a continuing demand for booster shots against SARS-CoV-2, ocular adverse events following the coronavirus disease-2019 (COVID-19) vaccines can cause significant visual impairment, and they warrant a high awareness and detailed documentation of possible ocular inflammatory manifestations. We present a case series of 11 patients presenting with ocular manifestations relevant to vaccine-associated autoimmune response within 6 weeks after the vaccination of the Oxford–AstraZeneca, the Moderna, and Pfizer-BioNTech vaccines at the main tertiary referral center in the most populated and most vaccinated city in Taiwan. Their diagnosis included five acute anterior uveitis, two multiple evanescent white dot syndrome, one probable Vogt–Koyanagi–Harada disease, one anterior scleritis, one relapsed idiopathic panuveitis, and one autoantibody-related central retinal artery occlusion. This report presented a broad spectrum of the ocular inflammatory events following the vaccination of COVID-19. Early recognition of the clinical manifestations mentioned herein with prompt management is crucial in recovering the patients' vision.

show abstract

De Novo Vogt-Koyanagi-Harada Disease following Covid-19 Vaccine: A Case Report and Literature Overview

Cited by 14 publications

References 15 publications

De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy

De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

Ocular inflammatory manifestations following COVID-19 vaccinations in Taiwan: A case series

Contact Info

Product

Resources

About